The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non–Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy
BACKGROUND: MUC5B is glycoprotein secreted by bronchial glands. A promoter variant in MUC5B, rs35705950, was previously found to be strongly associated with the incidence of idiopathic pulmonary fibrosis (IPF) and also the overall survival (OS) of such patients. Patients with IPF and patients with r...
Main Authors: | Ju Yang, Ting Xu, Daniel R. Gomez, Melenda Jeter, Lawrence B Levy, Yipeng Song, Stephen Hahn, Zhongxing Liao, Xianglin Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-04-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523316302443 |
Similar Items
-
Prognostic Factors for Patients with Esophageal Cancer Receiving Definitive Radiotherapy Alone: A Retrospective Analysis
by: Jiang N, et al.
Published: (2021-04-01) -
Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC
by: Jagoda Philippe, et al.
Published: (2021-01-01) -
Heart Dosimetric Parameters Were Associated With Cardiac Events and Overall Survival for Patients With Locally Advanced Esophageal Cancer Receiving Definitive Radiotherapy
by: Guoxin Cai, et al.
Published: (2020-03-01) -
Correction to: Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC
by: Philippe Jagoda, et al.
Published: (2021-02-01) -
Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy.
by: Ming Yin, et al.
Published: (2011-01-01)